Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France

Hum Vaccin Immunother. 2024 Dec 31;20(1):2387221. doi: 10.1080/21645515.2024.2387221. Epub 2024 Aug 14.

Abstract

France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.

Keywords: COVID-19; immunocompromised; prophylaxis.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • COVID-19 Drug Treatment
  • COVID-19* / prevention & control
  • Female
  • France
  • Humans
  • Immunocompromised Host*
  • Male
  • Middle Aged
  • Pre-Exposure Prophylaxis* / methods
  • SARS-CoV-2 / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.